Westwind Capital Purchases New Holdings in Solventum Corporation $SOLV

Westwind Capital acquired a new stake in shares of Solventum Corporation (NYSE:SOLV) in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 18,663 shares of the company’s stock, valued at approximately $1,645,000.

A number of other large investors have also recently made changes to their positions in the stock. NewEdge Advisors LLC boosted its stake in shares of Solventum by 2.2% during the first quarter. NewEdge Advisors LLC now owns 6,707 shares of the company’s stock valued at $438,000 after purchasing an additional 144 shares during the period. HB Wealth Management LLC increased its stake in Solventum by 3.5% in the 1st quarter. HB Wealth Management LLC now owns 4,292 shares of the company’s stock worth $280,000 after buying an additional 147 shares during the period. Clearstead Trust LLC lifted its holdings in Solventum by 61.0% during the 1st quarter. Clearstead Trust LLC now owns 396 shares of the company’s stock valued at $26,000 after buying an additional 150 shares in the last quarter. Empirical Finance LLC boosted its position in Solventum by 3.6% in the 2nd quarter. Empirical Finance LLC now owns 5,074 shares of the company’s stock valued at $391,000 after buying an additional 174 shares during the period. Finally, Caitong International Asset Management Co. Ltd boosted its position in Solventum by 80.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 429 shares of the company’s stock valued at $34,000 after buying an additional 191 shares during the period.

Solventum Stock Up 0.6%

Shares of NYSE SOLV traded up $0.56 during mid-day trading on Thursday, reaching $86.44. 1,286,542 shares of the company were exchanged, compared to its average volume of 1,313,969. Solventum Corporation has a 1 year low of $62.38 and a 1 year high of $94.16. The firm has a 50-day moving average of $88.54 and a 200 day moving average of $79.07. The stock has a market cap of $14.71 billion, a price-to-earnings ratio of 10.57, a P/E/G ratio of 1.36 and a beta of 0.63. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 1.00.

Solventum (NYSE:SOLV) last posted its earnings results on Wednesday, August 5th. The company reported $2.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.91 by $0.64. The company had revenue of $2.21 billion for the quarter, compared to analyst estimates of $2.15 billion. Solventum had a return on equity of 25.09% and a net margin of 17.26%.The firm’s quarterly revenue was up 2.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.69 earnings per share. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. On average, research analysts expect that Solventum Corporation will post 7.22 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Wall Street Zen raised shares of Solventum from a “hold” rating to a “buy” rating in a research report on Saturday, September 12th. Mizuho set a $113.00 price objective on Solventum in a report on Thursday, August 6th. UBS Group lifted their target price on Solventum from $95.00 to $101.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. KeyCorp increased their price target on Solventum from $93.00 to $102.00 and gave the stock an “overweight” rating in a research report on Thursday, August 6th. Finally, Jefferies Financial Group restated a “buy” rating on shares of Solventum in a report on Thursday. Ten research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $92.80.

Solventum Company Profile

Solventum Corporation (NYSE:SOLV) is a global healthcare company that develops products, technologies and services designed to support clinical care, healthcare operations and patient outcomes. The company serves healthcare providers, dental professionals, laboratories, manufacturers and other organizations.

Solventum’s portfolio includes medical and surgical products such as wound-care systems, surgical drapes, sterilization and infection-prevention solutions, and patient-monitoring or fixation products.